MedTrace Logo

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04129944 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2021-12-29

Study results available
· View outcomes & findings →

Summary

A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

UBX0101

Investigational drug intra-articular injection

OTHER

Placebo

Placebo intra-articular injection

Sponsors & Collaborators

  • Unity Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · UNITY Biotechnology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2020-05-20
Completion
2020-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129944 on ClinicalTrials.gov